London – Arena International announced today the first-ever Direct-to-Patient and Virtual Clinical Trials (https://arena-international.com/dtpvirtual/) will be held as a Digital Experience on Thursday, 9 July 2020. As COVID-19 has forced the market to move towards decentralized and remote models, this event provides the perfect opportunity for clinical trial professionals to hear, meet and learn from top-class speakers around the world to discuss challenges and innovations in this critical time.
In order for viruses to proliferate, they usually need to be supported by infected cells. In many cases, the molecules they need to replicate their own genetic material are only found in the nucleus of the host cell before infecting other cells in the vicinity. But not all viruses enter the nucleus. Some viruses stay in the cytoplasm and must therefore be able to replicate their genetic material independently. To do so, they must bring their own "machined parts". A key player in this process is a specialized enzyme, RNA polymerase, composed of various subunits. This enzyme reads genetic information from the viral genome and transcribes it into messenger RNA (mRNA) and uses mRNA as a blueprint for proteins encoded in the genome.
About one in three human proteins is understudied. Even when quantifying data is available from multiple sources, "dark" genes and proteins are simply not well characterized (Figure 1).
Are you curious where dark gene hunting leads? There are a number of resources:
Things like gene editing, stem cells, immunotherapies and new types of biologics are now mega-trends in the pharmaceutical industry, widely covered in media, and I guess there is little doubt that biology is the next big thing in medicine. However, in this post I would like to outline several hot areas in small molecule drug discovery, suggesting a lot of untapped potential and investment prospects in this more “traditional” pharmaceutical research space.
Immunotherapies are hot property. Immuno-oncology is the crown jewel. But the road to riches, and more importantly cancer cures, is now crowded and full of potholes. Drug hunters need to look ahead, beyond the discovery process itself, to the reality of the many impediments that will confront drug candidates as they proceed towards the clinic in today's landscape. Here, I present three insights from current events, the third one taking a contrarian position.